Abstract：Objective To observe the curative effect of intranasal high flow oxygen therapy for type Ⅰ failure and Ⅱ respiratory failure with no obvious carbon dioxide retention. Methods A total of 60 patients with type Ⅰ failure and Ⅱ respiratory failure with no obvious carbon dioxide retention were selected as the research subjects from July 2019 to March 2020 in the Department of Respiratory Medicine of the Changshu NO.2 People’s Hospital, Jiangsu Province, according to numerical odd-even method, they were divided into control group and observation group, with 30 cases in each group. The control group was treated with non-invasive positive pressure ventilation, and the observation group was treated with transnasal high-flow oxygen therapy. The effective rate of treatment was compared between the two groups, blood gas analysis indexes, hemodynamic indexes, comfort score and Borg score were recorded before and after treatment, and the incidence of adverse events during treatment was observed between the two groups. Results The total effective rate of observation group was higher than control group, and the difference was statistically significant (P ＜ 0.05). After treatment, the levels of oxygen saturation (SpO2) and oxygen partial pressure (SaO2) in the two groups were significantly higher than before treatment, the level of carbon dioxide partial pressure (PaCO2) was lower than before treatment, and after treatment, the levels of PaO2 and SaO2 in the observation group were higher than the control group, while the levels of PaCO2 was lower than the control group, with statistical significance (P ＜ 0.05). After treatment, heart rate (HR), respiratory rate (RR) and pulmonary artery pressure (PAP) in the two groups were lower than before theatment, and the observation group was lower than the control group, the differences were statistically significant (P ＜ 0.05). After treatment, the comfort scores of the two groups were higher than before treatment, the Borg scores were lower than before treatment, and the comfort score of the observation group was higher than the control group, and the Borg score was lower than the control group, and the differences were statistically significant (P ＜ 0.05). The incidence of adverse events in observation group was lower than that in control group, and the difference was statistically significant (P ＜ 0.05). Conclusion Transnasal high-flow oxygen therapy can significantly improve the clinical symptoms and oxygen status for typeⅠfailure and Ⅱ respiratory failure with no obvious carbon dioxide retention, and improve the comfort level and reduce the occurrence of adverse events.
由振华 黄锦宏 赵云根 顾宇平. 经鼻高流量氧疗在I型呼吸衰竭和二氧化碳潴留不明显的Ⅱ型呼吸衰竭中的疗效[J]. 中国医药导报, 2021, 18(16): 82-85,90.
YOU Zhenhua HUANG Jinhong ZHAO Yungen GU Yuping. Efficacy of intranasal high flow oxygen therapy for type Ⅰ respiratory failure and type Ⅱ respiratory failure with no obvious carbon dioxide retention. 中国医药导报, 2021, 18(16): 82-85,90.
京公网安备 11010502046598号